Interestingly, emerging oncology and non-oncology drugs such as the HDAC inhibitors (Yoon and Eom, 2016) and miglustat, an approved drug for Gaucher’s disease (Barth et al., 2013), were amongst potential drug repurposing candidates that target fitness genes in tractability group 1 (targeting HDAC2 and UGCG respectively). The gene discussed is HDAC2; the disease is Gaucher disease.